eMeasure Name | Cervical Cancer Screening | eMeasure Id | 193ED38C-7C8F-43DF-BB18-3EA7B19A23D3 |
Version number | 1 | eMeasure Set Id | 6910C0F3-5879-4419-ACE0-786C2944C5D3 |
Available Date | No information | Measurement Period | January 1, 20xx through December 31, 20xx |
Measure Steward | National Committee for Quality Assurance | ||
Endorsed by | National Quality Forum | ||
Description | The percentage of women 21-63 years of age who received one or more Pap tests to screen for cervical cancer. | ||
Copyright | © National Committee for Quality Assurance. All Rights Reserved |
||
Measure scoring | Proportion | ||
Measure type | Process | ||
Stratification | None |
||
Risk Adjustment | None |
||
Data Aggregation | |||
Rationale | American Cancer Society (ACS, Nov 2002): Test approximately 3 years after onset of vaginal intercourse, but no later than age 21; intervals annually, every 2-3 years for women >=30 with 3 negative cytology tests. U. S. Preventive Services Task Force (USPSTF, Jan 2003): Test within 3 years of onset of sexual activity or age 21, whichever comes first; intervals of at least every 3 years. American College of Obstetricians and Gynecologists (ACOG, Aug 2003): Approximately 3 years after onset of sexual intercourse, but no later than age 21; annually, every 2-3 years for women >=30 with 3 negative cytology tests. |
||
Clinical Recommendation Statement | This measure assesses the percentage of women in a specific age demographic who receive appropriate screening for cervical cancer. The American Cancer Society predicted that in 2009, nearly 11,270 women would be newly diagnosed with cervical cancer and 4,070 women would die of cervical cancer. The financial burden is also noteworthy: treatment for cervical cancer cost about $2 billion in 2004 (CDC). The American Cancer Society reported that screening can save lives, stating that the overall five-year survival rate for cervical cancer is nearly 71%, with a survival rate of 92% for detection in the earliest stage (2010). This evidence is corroborated by the fact that from 1955-1992, the mortality rate from cervical cancer declined by 74% because of screening. This measure facilitates efforts toward early detection of cervical cancer and acceleration of treatment upon diagnosis. |
||
Improvement notation | Higher score indicates better quality |
||
Measurement duration | 36 month(s) |
||
Reference | USPSTF. Screening for Cervical Cancer. Jan 2003. Available at: http://www.ahcpr.gov/clinic/uspstf/uspscerv.htm |
||
Reference | American Cancer Society. Cancer Facts & Figures 2005. Atlanta: American Cancer Society; 2005. |
||
Definition | Initial Patient Population(s): All female patients 24 to 64 years of age during the measurement period. |
||
Definition | Denominator(s): Patients in the initial population with an encounter during measurement period. |
||
Definition | Denominator Exclusion(s): Female patients who had a hysterectomy with no residual cervix |
||
Definition | Numerator(s): The number of female patients who had one or more Pap tests during the measurement period |
||
Definition | Denominator Exception(s): N/A |
||
Guidance | Note: Given the measurement look back period, women 18 to 64 years of age as of December 31 of the measure period will be captured in this measure. |
||
Supplemental Data Elements | Report "Patient Characteristic: Gender" using "Gender HL7 Value Set (2.16.840.1.113883.1.11.1)"; Report "Patient Characteristic: Race" using "Race CDC Value Set (2.16.840.1.114222.4.11.836)"; Report "Patient Characteristic: Ethnicity" using "Ethnicity CDC Value Set (2.16.840.1.114222.4.11.837)"; Report "Patient Characteristic: Payer" using "Payer Source of Payment Typology Value Set (2.16.840.1.113883.3.221.5)". |
Measure set | CLINICAL QUALITY MEASURE SET 2011-2012 |